Ovid Therapeutics reports Q3 2021 net loss of $11.4M, cash $201.8M, and business development strategy

Ovid Therapeutics Inc.

2021-Q3 EPS reported $2.14 revenue$221,000,000

Cash and equivalents $201.8M as of Sept 30, 2021; net loss $11.4M ($0.17 per share) vs $16.4M ($0.28) in Q3 2020.
Revenue zero vs $6.9M in Q3 2020; R&D expenses down to $4.9M from $15.9M due to OV101 wind-down and soticlestat termination.
Soticlestat Phase 3 trials for Lennox-Gastaut and Dravet enrolling; Ovid eligible for up to 20% royalties on global sales.
Ovid plans to pursue business development for precision therapeutics; targets IND submission for OV329 in 2022.
Kevin Fitzgerald, Ph.D., former Alnylam CSO, appointed to Board of Directors.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.